Immunosuppressants

Advanced Intermediate for Apremilast 

Vedolizumab is an anti-α4β7 integrin mAb for ulcerative colitis and Crohn's disease. Its gut-selective anti-lymphocyte trafficking mechanism avoids systemic immunosuppression and PML risk, making it the preferred safety option among IBD biologics.

Description: Oral immunomodulatory medication used primarily in the treatment of relapsing forms of multiple sclerosis. It helps reduce disease activity and progression.

Therapeutic Category: Immunomodulator / Neurology

Mechanism of Action (MOA): ...

Under Development

Cerata Pharmaceuticals is the leading manufacturer of Tacrolimus API in IP/BP/USP/EP grade and offers high-quality products with the highest levels of compliance and our API products are trusted by pharmaceutical companies in over 90 countries, reflecting our global footprint and reputation.

...

Azathioprine

Used to prevent organ rejection following kidney, heart, or liver transplantation.

Deflazacort

For the reduction and neutralization of toxic effects of folic acid antagonists, such as methotrexate.
INJ.SOL. 200mg/20mL
BT x 1 vial x 20mL

Immunosuppressant

Azathioprine Tablets- 25mg, 50mg

Therapeutic Area: Immunology

Status: Early

USA approved

USDMF, CEP available.

Secukinumab is an anti-IL-17A mAb and the pathway leader in psoriasis, ankylosing spondylitis, and psoriatic arthritis. With industry-leading long-term PASI 100 clearance rates, it is a mature, high-volume immunology asset with stable market share.

Ocrelizumab is an anti-CD20 mAb and the only approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS). With semiannual infusion and nearly 50% reduction in annualized relapse rate for RMS, it holds an unmatched position in neuroimmunology.

Risankizumab is an anti-IL-23 p19 mAb for psoriasis, Crohn's disease, and ulcerative colitis. With industry-leading PASI 90 response rates and q12w maintenance dosing, it offers exceptional compliance and ranks among the fastest-growing assets in immunology.

Immunosuppressant

Immunosuppressant

Therapeutic Area: ANCA-Associated Vasculitis(AAV) ANCA

Status: Early